BCL2 and acute myeloid leukemia: The dependence of BCL-2 activity has been demonstrated in both chemosensitive and chemoresistant myeloblasts but not in normal hematopoietic stem cells (HSCs) (Vo et al., 2012); therefore, the use of BCL-2 inhibitors has recently emerged, especially the use of venetoclax in the treatment of AML (Griffioen et al., 2022).